Potentiation and inhibition of migration of human neutrophils by auranofin

Jan G R Elferink, Ben M de Koster

Abstract

Objectives—As auranofin resembles some neutrophil activating sulphur containing compounds, it was decided to investigate whether it had activating effects on neutrophil migration in addition to the published inhibitory effects.

Methods—The Boyden chamber assay was used to determine the migration velocity of human neutrophils. The difference between chemotaxis and chemokinesis was established with a chequerboard assay.

Results—Low concentrations of auranofin stimulated human neutrophil migration; concentrations of auranofin higher than 1 μmol/l were inhibitory. Inhibitors of leukotriene formation, or of protein kinase C, had the same effect on auranofin induced potentiation of migration as on fMLP activated migration. Auranofin, at a concentration of 100 nmol/l, caused a transient increase in the cGMP level of neutrophils. The auranofin induced increase in migration was strongly inhibited by methylene blue and by LY83583, two inhibitors of cGMP accumulation.

Conclusions—The auranofin induced enhancement of migration is partly due to a chemokinetic effect, but mainly due to a chemotactic effect. The potentiating effect of auranofin on migration is not specifically due to the ability of the drug to inhibit protein kinase C activity or to generate leukotrienes. These results suggest that the enhancement of neutrophil migration by low levels of auranofin is related to the enhancement of cGMP levels in neutrophils.

A number of other functions of the stimulated neutrophil are inhibited by auranofin. These include aggregation, phagocytosis, the release of lysosomal enzymes and leukotrienes, and the respiratory burst. Auranofin inhibits some cellular processes which might be related to inhibition of the functions. Protein kinase C activity, and the associated protein phosphorylation, are inhibited by auranofin. The drug inhibits the number of microtubules in resting neutrophils and decreases the surface charge and membrane potential of these cells.

A number of studies have shown that auranofin is not only inhibitory but is also able to potentiate some functions and processes in the neutrophil and in other cell types. Although micromolar concentrations of auranofin inhibited the effect of phorbol myristate acetate, lower concentrations enhanced phorbol myristate acetate induced superoxide production. Low concentrations of auranofin stimulated interleukin-2 production, whereas high concentrations were inhibitory. Synthesis of leukotrienes was enhanced by low concentrations of auranofin. Auranofin may apparently show activating and inhibitory effects, depending on the conditions.

It has been found that a number of sulphur containing disease modifying drugs have a potentiating effect on migration and exocytosis by neutrophils. As there are some similarities between these compounds and auranofin, we decided to investigate whether auranofin has activating effects on neutrophil migration in addition to the published inhibitory effects.

Materials and methods

Isolation of neutrophils

Human neutrophils were isolated from the venous blood of healthy volunteers using dextran sedimentation followed by centrifugation over Ficoll-Isoaque and hypotonic haemolysis of contaminating erythrocytes. Isolated neutrophils were resuspended in a medium containing 140 mmol/l NaCl, 5 mmol/l KCl, 10 mmol/l glucose, 20 mmol/l HEPES (pH 7.3), and 0-5% bovine serum albumin. The final neutrophil concentration during the experiments was 3×10⁷/ml.

Migration measurements

Cell migration was measured with the Boyden chamber technique as described by Boyden.

The two compartments of the chamber were separated by a cellulose acetate Millipore filter.
with a pore size of 3 μm. Medium supplemented with 1 mmol/l Ca²⁺ and 1 mmol/l Mg²⁺ was present in the upper and lower compartments, unless otherwise indicated. Neutrophils were placed in the upper compartment of the chamber then incubated for 40 minutes at 37°C. After migration the filters were fixed and stained and the distance travelled in micrometres into the filter was determined according to the leading front technique.²⁰

CYCLIC GMP ASSAY
Neutrophils (150 µl; final concentration 2×10⁷ cells/ml) were exposed to reagents at 37°C for the indicated time. Subsequently 150 µl 3-5% perchloric acid was added, and the resulting mixture was stored overnight in a freezer. The solution was neutralised by adding 75 µl saturated (22°C) NaHCO₃. After 10 minutes the mixture was centrifuged. To 100 µl supernatant 50 µl radioactive cGMP and 50 µl antibody from the radioimmunoassay kit (Amersham) were added. After mixing the solution was stored on ice for 90 minutes, after which 1 ml ice cold 60% (NH₄)₂SO₄ was added. The solution was mixed and stored on ice for a further 10 minutes, then centrifuged. The supernatant was carefully removed and the residue taken up in 1 ml water. A 1 ml volume of the solution was mixed with 4 ml scintillation fluid (299, Packard), and counted in a scintillation counter. Known amounts of cGMP were treated in the same way as the cells and were used for the calibration graph.

STATISTICAL ANALYSIS
Chemoattract assays were carried out in triplicate and the migration distance of the neutrophils was determined at five different filter sites. All mean values are arithmetical means (SEM), calculated on the basis of all 15 determinations. The significance was calculated with Student’s t test; p<0.01 was considered as statistically significant.

Results
Random migration by neutrophils was stimulated if auranofin was present in the lower compartment of the Boyden chamber in the concentration range up to 1 μmol/l (fig 1). Maximum stimulation occurred at a concentration of 0-1 μmol/l auranofin. Concentrations of auranofin higher than 1 μmol/l inhibited random locomotion.

The effect of auranofin strongly depended on the location of the drug with respect to the cells, and whether or not a chemotactic agent was present (table 1). The activating effect was strong when auranofin (1×10⁻⁷ mol/l) was present in the lower compartment only. When the drug was present in the two compartments the effect was moderate, and the effect was small when auranofin was present in the upper compartment with the cells.

The effect of auranofin on fMLP induced chemotaxis was tested. Auranofin (10⁻⁴ mol/l) had little effect when the chemotactic agent fMLP was present in the lower compartment. A concentration of 20 μmol/l auranofin was inhibitory, not only on random migration but especially on fMLP induced chemotaxis; the effect was most pronounced when the drug was present in the two compartments of the Boyden chamber (table 1).

A chequerboard assay was carried out to establish the relative contributions of chemokinesis and chemotaxis in auranofin stimulated neutrophil migration. Migration was higher than calculated on the basis of chemokinesis alone when the concentration of auranofin in the lower compartment was higher than in the upper compartment. The reverse was true when the concentration below the filter was lower than in the upper compartment (table 2).

To determine the possible involvement of leukotriene B₄ in auranofin induced enhancement of migration, several inhibitors of leukotriene formation were tested. These inhibitors (naproxen, felodipine, nordihydroguaiaretic acid, and quercetin) were tested in concentrations which are known to inhibit strongly leukotriene formation. As a control the effect of these inhibitors on fMLP induced migration was tested. Inhibition of auranofin induced migration was about the same as that of fMLP induced migration (table 3). As auranofin affects protein kinase C mediated neutrophil functions the same procedure was followed to determine a role for protein kinase C in the activating effect of auranofin. Two specific inhibitors of protein kinase C, staurosporine and 1-O-hexadecyl-2-O-methylglycerol (AMG-C₁₆O₂) gave no more inhibition of migration with auranofin as an activating agent than with fMLP.

Auranofin, at a concentration of 1×10⁻⁷ mol/l, enhanced the cGMP level of resting neutrophils. The effect is transient, and a

<table>
<thead>
<tr>
<th>Concentration of auranofin (mol/l) present in</th>
<th>Migration towards filter (μm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lower compartment</td>
<td>Upper compartment</td>
</tr>
<tr>
<td>No additive</td>
<td>fMLP</td>
</tr>
<tr>
<td>1×10⁻¹</td>
<td>1×10⁻¹</td>
</tr>
<tr>
<td>1×10⁻²</td>
<td>1×10⁻²</td>
</tr>
<tr>
<td>1×10⁻³</td>
<td>1×10⁻³</td>
</tr>
<tr>
<td>2×10⁻⁴</td>
<td>2×10⁻⁴</td>
</tr>
<tr>
<td>2×10⁻³</td>
<td>2×10⁻³</td>
</tr>
<tr>
<td>1×10⁻²</td>
<td>1×10⁻²</td>
</tr>
<tr>
<td>2×10⁻³</td>
<td>2×10⁻³</td>
</tr>
</tbody>
</table>

fMLP=1×10⁻⁷ mol/l fMet-Leu-Phe, present in the lower compartment of the Boyden chamber.
Effect of auranofin on neutrophil migration

Table 2  Migration of neutrophils in different absolute concentrations and concentration gradients of auranofin

<table>
<thead>
<tr>
<th>Concentration of auranofin in upper compartment (mol/l)</th>
<th>Concentration of auranofin in lower compartment (mol/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>1 x 10^{-6}</td>
</tr>
<tr>
<td>1 x 10^{-4}</td>
<td>1 x 10^{-3}</td>
</tr>
<tr>
<td>5 x 10^{-4}</td>
<td>5 x 10^{-3}</td>
</tr>
</tbody>
</table>

Values given represent the mean (SEM) migration (mm) after an incubation time of 40 minutes, in the presence of the indicated concentrations of auranofin below and above the filter. The values in square brackets are the migration values expected on the basis of the effects of chemokinesis alone (calculated according to Zigmund and Hirsch9).

Table 3  Inhibition of fMLP or auranofin enhanced migration of neutrophils by inhibitors of leukotriene formation or protein kinase C inhibitors

<table>
<thead>
<tr>
<th>Inhibitor*</th>
<th>Migration towards (µm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>fMLP</td>
<td>Auranofin</td>
</tr>
<tr>
<td>50 µmol/l naproxen</td>
<td>90-2 (1-4)</td>
</tr>
<tr>
<td>5 µmol/l felodipine</td>
<td>90-3 (1-7)</td>
</tr>
<tr>
<td>10 µmol/l NDGA</td>
<td>80-9 (1-3)</td>
</tr>
<tr>
<td>10 µmol/l quercetin</td>
<td>85-2 (1-9)</td>
</tr>
<tr>
<td>100 nmol/l staurosporine</td>
<td>80-6 (1-5)</td>
</tr>
<tr>
<td>100 µmol/l AMG-C6</td>
<td>91-3 (1-6)</td>
</tr>
</tbody>
</table>

NDGA=Nordihydroguaiaretic acid; AMG-C6=1-O-hexadecyl-2-methylglycerol. Auranofin (1 x 10^{-3} mol/l) and fMLP (1 x 10^{-3} mol/l) were present in the lower compartment only. Migration in the absence of activating agent was 43-8 (1-7) µm.

maximum effect was observed after the incubation of neutrophils for about five minutes with auranofin (fig 2).

Methylene blue, an inhibitor of cGMP accumulation, had little effect on random migration, but inhibited the enhancement of migration induced by a low concentration of auranofin. The inhibitory effect of a higher concentration of auranofin on fMLP induced migration was not decreased by methylene blue (table 4). LY83583, an inhibitor of guanylate cyclase, gave the same effects as methylene blue; the inhibitory effects were even more pronounced (table 4). Methylene blue and LY83583 were tested to see whether they inhibited auranofin induced cGMP accumulation in neutrophils under the conditions of our experiments. Although auranofin (1 x 10^{-3} mol/l, incubation time five minutes) gave an increase of cGMP from 2-5 (0-2) to 12-6 (1-6) pmol/l in cells, the increase was reduced to 1-9 (0-4) pmol/l cells in the presence of methylene blue, and to 2-3 (0-3) pmol/l cells in the presence of LY83583. The inhibitors had little effect on the cGMP level of resting cells.

Discussion

The results presented here show that auranofin not only has inhibitory effects on migration, but that at low concentrations the drug stimulates neutrophil migration. The stimulating effect is partly chemokinetic because migration is enhanced when auranofin is present in the upper and lower compartments of the Boyden chamber. The strongest enhancement of migration is observed when the drug is present in the lower compartment only, indicating that auranofin also has chemotactic properties.

The relative contribution of chemokinesis and chemotaxis in the activating effect of auranofin on neutrophil migration can be derived from the chequerboard assay. This shows that chemotaxis and chemokinesis contribute to the enhancing effect on neutrophil migration. The chemotactic component, however, is stronger than the chemokinetic component.

At low concentrations auranofin stimulates leukotriene B4 generation. As this leukotriene is chemotactic it is conceivable that a relation exists between the generation of the leukotriene and the enhanced motility induced by auranofin. A series of inhibitors of leukotriene generation, however, had little effect on auranofin induced migration, and if there was a slight inhibition it was not more than for fMLP induced migration. This makes it unlikely that leukotriene formation affects the potentiating effect of auranofin on neutrophils. Protein kinase C activity is required for the synthesis of leukotriene B4 in neutrophils. Auranofin modulates some leucocyte functions by interacting with protein kinase C. Two inhibitors of protein kinase C, in concentrations which completely inhibit the enzyme, have no more effect on auranofin induced migration than for fMLP induced migration. This suggests that the potentiating effect of auranofin on migration is not specifically mediated by protein kinase C, and supports the view that leukotrienes do not play a part in this potentiating effect.
A possible role for cGMP in neutrophil migration has been suggested. A number of different agents which have an enhancing effect on the cGMP level of cells also stimulate neutrophil migration. These agents include ascorbic acid,7 levamisole,27 acetyl choline,27 p-penicillamine,12 and others.28 Auranofin also causes an enhancement of the cGMP level in neutrophils. Though the role of cGMP in neutrophil functions is far from clear, it seems tempting to speculate that the enhancement of the cGMP level, or a process which is associated with this enhancement, is related to the activating effect of auranofin on neutrophil migration.

Apart from the enhancement of the cGMP level some other results support the hypothesis that cGMP plays a part in the activating effect of auranofin. Methylene blue and LY83583 are known inhibitors of cGMP accumulation which act via an interference with guanylate cyclase.30 They completely inhibit the auranofin induced enhancement of cGMP level in neutrophils. The auranofin induced enhancement of migration is equally completely inhibited by these agents, whereas they have moderate effects on random migration and FMLP activated chemotaxis.

The inhibitory effect of auranofin, which occurs at higher concentrations of the drug, is in contrast to the activating effect not affected by methylene blue. This suggests that the activating and inhibitory effect are not due to a concentration dependent effect of the same agent, such as cGMP.

Inhibition of neutrophil migration has been proposed as a possible explanation of the beneficial effect of the drug in rheumatoid arthritis because the neutrophil is considered as an important mediator in inflammatory disorders. The serum concentration of gold during the treatment of rheumatoid arthritis with auranofin is about 0.7 μg/ml (40 μg/ml auranofin).22 From this amount about 90% is bound to serum proteins. The resulting free concentration of auranofin, about 0.4 μmol/l, lies in the range where activating effects might occur on neutrophil migration and other functions. It seems evident that there is no simple correlation between the beneficial effect of auranofin in rheumatoid arthritis and the effect of the drug on neutrophil functions, including migration. More studies are required to solve this paradoxical situation.